Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Deucravacitinib demonstrated significant improvements in Psoriasis Area and Severity Index (PASI) scores (PASI 75, PASI 90, PASI 100) compared to placebo and apremilast at week 16, indicating superior efficacy in achieving these thresholds of skin clearance.
• Physician’s Global Assessment (PGA) showed that Deucravacitinib was more effective than placebo and apremilast in achieving a score of 0/1, with the exception of the 3 mg every other day dose, further supporting its superior performance in assessing disease severity.
• Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) scores significantly improved with Deucravacitinib, reflecting better quality of life and symptom control in patients with moderate to severe plaque psoriasis.
• The most commonly reported adverse event for Deucravacitinib was nasopharyngitis, with a generally low and balanced incidence of adverse events across groups in most studies.
• No significant difference in serious adverse events (SAEs) between Deucravacitinib and placebo, and Deucravacitinib had a low incidence of SAEs and treatment discontinuation due to adverse events.
• There is no population types or subgroups information available in the reviewed documents.